Arvinas Stock Forecast, Price & News

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

How has Arvinas' stock price been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 52.7% and is now trading at $67.29.
View which stocks have been most impacted by COVID-19.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in December. As of December 15th, there was short interest totaling 2,430,000 shares, an increase of 38.9% from the November 30th total of 1,750,000 shares. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is currently 6.0 days. Approximately 5.5% of the shares of the stock are short sold.
View Arvinas' Short Interest.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Arvinas.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $2.13 by $3.07. The business earned $9.28 million during the quarter, compared to the consensus estimate of $26.89 million. Arvinas had a negative net margin of 794.97% and a negative trailing twelve-month return on equity of 27.02%. The company's revenue for the quarter was up 22.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.79) EPS.
View Arvinas' earnings history.

What price target have analysts set for ARVN?

15 brokers have issued twelve-month target prices for Arvinas' shares. Their forecasts range from $108.00 to $170.00. On average, they anticipate Arvinas' share price to reach $130.54 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:

• John G. Houston, President, Chief Executive Officer & Director (LinkedIn Profile)
• Sean A. Cassidy, Chief Financial Officer (LinkedIn Profile)
• Ian Taylor, Chief Scientific Officer
• Ronald Peck, Chief Medical Officer (LinkedIn Profile)
• Kimberly Wehger, Vice President-Information Technology

Who are some of Arvinas' key competitors?

Some companies that are related to Arvinas include Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Organon & Co. (OGN), Biohaven Pharmaceutical (BHVN), Maravai LifeSciences (MRVI), Evotec (EVTCY), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX) and Legend Biotech (LEGN).
View all of ARVN's competitors.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.16%), Joel Isaacson & Co. LLC (0.09%), Polianta Ltd (0.03%), Endurance Wealth Management Inc. (0.00%), Cutler Group LP (0.00%) and Lindbrook Capital LLC (0.00%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Joel Isaacson & Co. LLC, and Endurance Wealth Management Inc.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

Which major investors are buying Arvinas stock?

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and Lindbrook Capital LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $67.29.

How much money does Arvinas make?

Arvinas has a market capitalization of $3.56 billion and generates $21.80 million in revenue each year. The company earns $-119.33 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 179 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].